Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels

Carlo A. Altamura, Fulgenzio Colacurcio, Massimo C. Kauri, Anna R. Moro, Fedele De Novellis

Research output: Contribution to journalArticlepeer-review

Abstract

1. 1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50-300 mg i.m. monthly dose) for 12 months. 2. 2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population. 3. 3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p <0.01) higher EPSE total scores compared to those with a duration of illness <10 yrs (Group 1). 4. 4. A positive correlation was found between the administered dose and haloperidol plasma levels. 5. 5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1. 6. 6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses.

Original languageEnglish
Pages (from-to)25-35
Number of pages11
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume14
Issue number1
DOIs
Publication statusPublished - 1990

Keywords

  • C
  • catatonic
  • D
  • DG
  • diagnosis
  • disorganized
  • EPSE
  • extrapyramidal side-effects rating scale
  • haioperidol decanoate
  • haloperidol
  • haloperidol decanoate
  • HL
  • HL-D
  • L/D
  • level/dose ratio
  • not performed
  • NP
  • P
  • paranoid
  • patient
  • pharmacokinetics
  • PL
  • plasma levels
  • PT
  • schizophrenia
  • SD
  • standard deviation
  • U
  • undifferentiated
  • years
  • yrs

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Fingerprint

Dive into the research topics of 'Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels'. Together they form a unique fingerprint.

Cite this